article thumbnail

High biologics demand spurs need for greater contract manufacturing

Pharmaceutical Technology

With new drugs on the market, companies are now looking for ways to manufacture recently approved biologics, and countries are racing to claim their corner – or maintain their decades-old market share. There are fewer sites for cell and gene therapies and vaccines – 90 companies with 127 facilities, as per GlobalData figures.

article thumbnail

After 2022 interest rate hikes spook investors, pharma M&A to resurge in late 2023

Pharmaceutical Technology

Pharma company merger and acquisition (M&A) activity in the first half of 2023 has remained relatively low, consistent with the second half of last year, but investors predict deals will increase later in 2023. Experts at PWC, Goldman Sachs, and Morgan Stanley agree that pharma-related M&A is expected to pick up in 2023.

article thumbnail

Global drug discovery hotspots: Glasgow, UK

Drug Discovery World

The new hub will become a part of the already thriving life sciences sector in the Glasgow area, most of which is centred around the university, the Cancer Research UK Scotland Institute and the BioCity cluster, making Glasgow and its surrounds one of the most important regions for drug discovery and development in the UK.

Drugs 75